Zobrazeno 1 - 10
of 457
pro vyhledávání: '"multi-kinase"'
Autor:
Shuzhen Lai, Peijing Li, Xiaohui Liu, Guihong Liu, Tieming Xie, Xing Zhang, Xiaoxuan Wang, Jing Huang, Yiqiang Tang, Zhigang Liu, Guoping Shen, Chaoming Li, Fangxiao Lu, Lei Wang, Fagui Jiang, Caixing Sun, Yuanyuan Chen, Ming Chen
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 5, Pp 433-444 (2024)
Objective: Glioblastomas are highly vascularized malignant tumors. We determined the efficacy and safety of the anti-angiogenic multi-kinase inhibitor, anlotinib, for a newly diagnosed glioblastoma. Methods: This multicenter, single-arm trial (NCT041
Externí odkaz:
https://doaj.org/article/a2b63723ef5849fca44ec8334a0db255
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract To provide evidence for optimization of multi-kinase inhibitors (MKIs) use in the clinic, we use the public database to describe and evaluate electrolyte disorders (EDs) related to various MKIs treated for renal cell carcinoma. We analyzed s
Externí odkaz:
https://doaj.org/article/4b0f3f4719dd498aa58e77d9dd4b8674
Publikováno v:
BMC Chemistry, Vol 18, Iss 1, Pp 1-27 (2024)
Abstract A receptor-based pharmacophore model describing the binding features required for the multi-kinase inhibition of the target kinases (VEGFR-2, FGFR-1, and BRAF) were constructed and validated. It showed a good overall quality in discriminatin
Externí odkaz:
https://doaj.org/article/309451449cf14190a33e324be15d16ed
Publikováno v:
Journal of Biomedical Science, Vol 31, Iss 1, Pp 1-19 (2024)
Abstract Translational research plays a key role in drug development and biomarker discovery for hepatocellular carcinoma (HCC). However, unique challenges exist in this field because of the limited availability of human tumor samples from surgery, t
Externí odkaz:
https://doaj.org/article/6ba36409b9364e0da6a985b1eecb5f11
Autor:
Caroline Busch, Theresa Mulholland, Michele Zagnoni, Matthew Dalby, Catherine Berry, Helen Wheadon
Publikováno v:
Cell Communication and Signaling, Vol 21, Iss 1, Pp 1-17 (2023)
Abstract Background Despite improved patient outcome using tyrosine kinase inhibitors (TKIs), chronic myeloid leukaemia (CML) patients require life-long treatment due to leukaemic stem cell (LSC) persistence. LSCs reside in the bone marrow (BM) niche
Externí odkaz:
https://doaj.org/article/fbe6d5d0bb3447628508594bc360d398
Publikováno v:
Cancer Medicine, Vol 12, Iss 13, Pp 13978-13990 (2023)
Abstract Hepatocellular carcinoma (HCC) is a major cause of death among patients with liver cirrhosis. The rise of immuno‐oncology has revolutionized treatment for advanced HCC. However, most pivotal randomized controlled trials have excluded patie
Externí odkaz:
https://doaj.org/article/747696b1fb5b4f988dbf26409b98fa8a
Autor:
Tetsuya Tachiiri, Hideyuki Nishiofuku, Shinsaku Maeda, Takeshi Sato, Shohei Toyoda, Takeshi Matsumoto, Yuto Chanoki, Kiyoyuki Minamiguchi, Ryosuke Taiji, Hideki Kunichika, Satoshi Yamauchi, Takahiro Ito, Nagaaki Marugami, Toshihiro Tanaka
Publikováno v:
Current Oncology, Vol 30, Iss 5, Pp 4779-4786 (2023)
We describe the clinical effects of short-term lenvatinib administration prior to conventional transarterial chemoembolization (cTACE) on tumor vasculature. Two patients with unresectable hepatocellular carcinoma underwent high-resolution digital sub
Externí odkaz:
https://doaj.org/article/a7ebffbb3b954d678910428e16486d42
Autor:
Aya Nishizawa, Eiji Shinozaki, Takeru Wakatsuki, Takahiro Satoh, Naoya Yamazaki, Shunsuke Oyamada, Keisuke Ariyoshi, Kota Kihara, Masahiro Tsuboi, Kensei Yamaguchi
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Regorafenib, a multikinase inhibitor, causes a high frequency of hand-foot skin reactions (HFSRs). The present study evaluated the efficacy of topical aluminum chloride, a perspiration suppressant, in reducing the severity of hand
Externí odkaz:
https://doaj.org/article/f015af072078406e892195341eb78f9f
Autor:
Abdallah E. Abdallah, Reda R. Mabrouk, Maged Mohammed Saleh Al Ward, Sally I. Eissa, Eslam B. Elkaeed, Ahmed B. M. Mehany, Mariam A. Abo-Saif, Ola A. El-Feky, Mohamed S. Alesawy, Mohamed Ayman El-Zahabi
Publikováno v:
Journal of Enzyme Inhibition and Medicinal Chemistry, Vol 37, Iss 1, Pp 573-591 (2022)
Based on quinazoline, quinoxaline, and nitrobenzene scaffolds and on pharmacophoric features of VEGFR-2 inhibitors, 17 novel compounds were designed and synthesised. VEGFR-2 IC50 values ranged from 60.00 to 123.85 nM for the new derivatives compared
Externí odkaz:
https://doaj.org/article/3af1c5c676984e4bb4c5c70fd837b96c
Publikováno v:
Journal of Saudi Chemical Society, Vol 27, Iss 5, Pp 101712- (2023)
Since the discovery of imatinib, the first tyrosine kinase inhibitor, in 2001, targeted therapy has become mainstream of cancer therapeutics. Despite the advantages in efficacy and low side effects compared with conventional chemotherapy, the success
Externí odkaz:
https://doaj.org/article/13faa1f36d8b46c6b99697862bfafc6b